{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:37:24Z","timestamp":1762043844488,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jns.2021.120041","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T13:02:32Z","timestamp":1635426152000},"page":"120041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["King's college progression rate at first clinical evaluation: A new measure of disease progression in amyotrophic lateral sclerosis"],"prefix":"10.1016","volume":"431","author":[{"given":"Alessandro","family":"Introna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giammarco","family":"Milella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Morea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Fraddosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Zoccolella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eustachio","family":"D'Errico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella Laura","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jns.2021.120041_bb0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jnnp.2010.235952","article-title":"PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study","volume":"82","author":"Chi\u00f2","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"15","key":"10.1016\/j.jns.2021.120041_bb0010","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.0b013e3181bc0141","article-title":"Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"73","author":"Miller","year":"2009","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.jns.2021.120041_bb0015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"sup1","key":"10.1016\/j.jns.2021.120041_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/21678421.2017.1363780","article-title":"A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis","volume":"18","author":"EDARAVONE (MCI-186) ALS 16 STUDY GROUP","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"10.1016\/j.jns.2021.120041_bb0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/jnnp-2018-319294","article-title":"Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II\/III randomised controlled study","volume":"90","author":"Kaji","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.jns.2021.120041_bb0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","article-title":"Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial","volume":"21","author":"Mora","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"issue":"10","key":"10.1016\/j.jns.2021.120041_bb0035","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00415-010-5609-1","article-title":"Progression in ALS is not linear but is curvilinear","volume":"257","author":"Gordon","year":"2010","journal-title":"J. Neurol."},{"issue":"Pt 3","key":"10.1016\/j.jns.2021.120041_bb0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/brain\/awr351","article-title":"A proposed staging system for amyotrophic lateral sclerosis","volume":"135","author":"Roche","year":"2012","journal-title":"Brain."},{"issue":"1","key":"10.1016\/j.jns.2021.120041_bb0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp-2013-306589","article-title":"Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis","volume":"86","author":"Chi\u00f2","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7\u20138","key":"10.1016\/j.jns.2021.120041_bb0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/21678421.2018.1484925","article-title":"Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach","volume":"19","author":"Thakore","year":"2018","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"issue":"3\u20134","key":"10.1016\/j.jns.2021.120041_bb0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/21678421.2018.1556696","article-title":"A standard operating procedure for King\u2019s ALS clinical staging","volume":"20","author":"Balendra","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"issue":"5","key":"10.1016\/j.jns.2021.120041_bb0060","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2021.120041_bb0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/jnnp-2020-323271","article-title":"Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone study 19","volume":"92","author":"Al-Chalabi","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2021.120041_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp-2013-306865","article-title":"Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials","volume":"86","author":"Balendra","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"19","key":"10.1016\/j.jns.2021.120041_bb0075","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.0000000000000951","article-title":"The PRO-ACT database","volume":"83","author":"Atassi","year":"2014","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.jns.2021.120041_bb0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"World Federation of Neurology Research Group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord."},{"issue":"2","key":"10.1016\/j.jns.2021.120041_bb0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","article-title":"Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS","volume":"66","author":"Kimura","year":"2006","journal-title":"Neurology."},{"issue":"3\u20134","key":"10.1016\/j.jns.2021.120041_bb0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/21678421.2014.897357","article-title":"Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale","volume":"15","author":"Balendra","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"issue":"5","key":"10.1016\/j.jns.2021.120041_bb0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neurol.2018.09.017","article-title":"Staging amyotrophic lateral sclerosis: a new focus on progression","volume":"175","author":"Corcia","year":"2019","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.jns.2021.120041_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fninf.2018.00036","article-title":"Unraveling the complexity of amyotrophic lateral sclerosis survival prediction","volume":"12","author":"Pfohl","year":"2018","journal-title":"Front Neuroinform."},{"key":"10.1016\/j.jns.2021.120041_bb0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12883-014-0197-9","article-title":"Factors predicting one-year mortality in amyotrophic lateral sclerosis patients--data from a population-based registry","volume":"14","author":"Wolf","year":"2014","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.jns.2021.120041_bb0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17482960701262392","article-title":"Early use of non-invasive ventilation prolongs survival in subjects with ALS","volume":"8","author":"Lechtzin","year":"2007","journal-title":"Amyotroph. Lateral Scler."},{"issue":"7","key":"10.1016\/j.jns.2021.120041_bb0115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1474-4422(18)30207-2","article-title":"Stage of prolonged survival in ALS","volume":"17","author":"Brooks","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.120041_bb0120","first-page":"1","article-title":"Comparison of the ability of the King\u2019s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis","author":"Luna","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3\u20134","key":"10.1016\/j.jns.2021.120041_bb0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/21678421.2016.1265565","article-title":"Comparison of the King\u2019s and MiToS staging systems for ALS","volume":"18","author":"Fang","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"issue":"9","key":"10.1016\/j.jns.2021.120041_bb0130","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/ene.13053","article-title":"Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study","volume":"23","author":"Ferraro","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2021.120041_bb0135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.jns.2021.120041_bb0140","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/jnnp-2015-310998","article-title":"Rate of disease progression: a prognostic biomarker in ALS","volume":"87","author":"Labra","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5\u20136","key":"10.1016\/j.jns.2021.120041_bb0145","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/21678421.2019.1587634","article-title":"Defining pre-symptomatic amyotrophic lateral sclerosis","volume":"20","author":"Benatar","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2102743X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2102743X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:57:31Z","timestamp":1758383851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2102743X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":29,"alternative-id":["S0022510X2102743X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120041","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"King's college progression rate at first clinical evaluation: A new measure of disease progression in amyotrophic lateral sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120041"}}